What antidepressant can be prescribed for a bilateral amputee with depression who denies suicidal ideation and is currently taking allopurinol, oxycodone, and amlodipine (Norvasc)?

Antidepressant Selection for Bilateral Amputee with Depression

Start sertraline 50 mg daily or escitalopram 10 mg daily as first-line treatment for this patient's depression. These SSRIs have no significant drug interactions with his current medications (allopurinol, oxycodone, amlodipine) and are well-tolerated second-generation antidepressants with established efficacy 1.

Rationale for SSRI Selection

The American College of Physicians guidelines strongly recommend selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences, as all have equivalent efficacy 1. For this bilateral amputee:

• No efficacy differences exist between second-generation antidepressants for major depression 1
• Sertraline or escitalopram are preferred because they have:
  • Clean side effect profiles
  • Minimal drug interactions with his current regimen
  • Lower sexual dysfunction rates than paroxetine 1
  • Better tolerability in patients with chronic pain 2

Critical Drug Interaction Considerations

Avoid fluoxetine and paroxetine in this patient due to documented interactions with amlodipine (Norvasc):

• SSRIs, particularly fluoxetine, sertraline, and paroxetine, can intensify amlodipine side effects including lower limb swelling, headaches, and hypotension 3
• This is especially problematic for a bilateral amputee who may already have circulation concerns
• The interaction occurs through CYP3A4 inhibition 3

Oxycodone considerations: While opioids can have antidepressant properties 4, continuing his current pain regimen while adding an antidepressant is appropriate. Monitor for serotonin syndrome if opioid doses are increased 5.

Alternative Options

If SSRIs are not tolerated, consider:

1. Duloxetine 60 mg daily - Highest-ranked antidepressant across multiple outcomes with moderate-to-high certainty evidence 2

   • Additional benefit: treats neuropathic pain common in amputees 6, 2
   • Caution: Can cause nausea initially; start at 30 mg for one week 6

2. Bupropion SR 150 mg twice daily - Lower sexual dysfunction rates than SSRIs 1

   • Avoid if seizure history present
   • May interact with oxycodone metabolism

3. Mirtazapine 15-30 mg at bedtime - If insomnia is prominent

   • Causes sedation and weight gain
   • Faster onset than other antidepressants 1

Monitoring Protocol

Begin monitoring within 1-2 weeks of starting treatment 1:

• Assess for worsening depression, agitation, or emergence of suicidal ideation (highest risk in first 1-2 months) 1
• SSRIs carry increased risk for suicide attempts compared to placebo, though patient currently denies SI 1
• Monitor blood pressure if using duloxetine or venlafaxine 6
• Check for lower extremity swelling if SSRI combined with amlodipine 3

Reassess efficacy at 6-8 weeks: If inadequate response (<30% pain/mood improvement), switch to alternative first-line agent or consider augmentation 1.

Treatment Duration

• First episode: Continue for 4-9 months after achieving remission 1
• Recurrent depression: Consider longer-term maintenance (≥2 years) 1

Special Considerations for Amputees

Research shows 26% of limb amputees have mild depression, 23% moderate, and 10% severe depression 7. Those with work-related amputations have higher rates of moderate-to-severe depression 7. Antidepressants can improve both mental health and pain outcomes in this population 7, making pharmacotherapy particularly valuable alongside any rehabilitation efforts.

Key pitfall to avoid: Do not use paroxetine as first-line due to highest sexual dysfunction rates and difficult discontinuation 1. Do not combine SSRIs with amlodipine without close monitoring for intensified calcium channel blocker side effects 3.